StockAxis

Marksans Pharma Ltd

Quarterly Result - Q3FY24

Marksans Pharma Ltd

Pharmaceuticals & Drugs - Global

Current

CMP
Rs. 158.50
Rating:
Hold
February 13, 2024

Previous

Rating:
Hold

Stock Info

BSE
524404
NSE
MARKSANS
Bloomberg
MRKS:IN
Reuters
MARK.BO
Sector
Pharmaceuticals & Drugs - Global
Face Value (Rs)
1
Equity Capital (Rs cr)
45
Mkt Cap (Rs cr)
7293.67
52w H/L (Rs)
179.30 - 64.05
Avg Daily Vol (BSE+NSE)
966,476

Shareholding Pattern

(as on 31-Dec)
%
Promoter
43.85
FIIs
15.55
DIIs
4.76
Public & Others
35.81
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
-1.68
14.37
138.78
Sensex
-2.42
10.20
18.41
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Marksans Pharma Ltd Sensex
Marksans Pharma Ltd
Source: Ace equity, StockAxis Research

Financial Highlights:

Particulars (Rs Crores) Q3FY24 Q3FY23 YoY Q2FY24 QoQ
Revenue 586.00 480.00 22.00% 531.00 10.00%
EBITDA 133.00 77.00 74.00% 114.00 17.00%
EBITDA Margin (%) 23.00% 16.00% 672 bps 21.00% 125 bps
PAT 83.00 63.00 31.00% 84.00 0.00%

Source: Company Filings; StockAxis Research

Q3FY24 Financial Performance
Marksans Pharma Limited delivered a healthy financial performance for the quarter ended Q3FY24. Consolidated Revenue increased by 22% to Rs. 586 Crores as against Rs 480 Crores for the same quarter of the previous year, driven by market share gains, new launches, the addition of new customers, an increase in share with existing customers, and incremental contributions from the acquired Teva facility. Consolidated EBITDA surged by 74% on a YoY basis to Rs 133 Crores, whereas the EBITDA margin expanded by 672 bps and stood at 23%, led by operating leverage benefits, cost optimization, and reduction in raw material prices. Consolidated PAT increased by 31% on a YoY basis to Rs 83 Crores, and the PAT margin stood at 14% followed by an expansion of 99bps.

Revenue from operations in Q3FY24 is at Rs 586.1 Crores, out of which US revenues are at Rs 258 Crores, UK and Europe revenues at Rs 251 Crores, and Australia and New Zealand revenues at Rs 49 Crores.

US Market
US & North America Formulation business reported growth of 19% YoY to Rs. 258 Crores in Q3FY24 on account of new product launches and due to an increase in the share of existing products.

UK and Europe Market
UK and Europe business registered a growth of Rs. 251 Crores from the UK and Europe Formulation business in Q3FY24 as compared to Rs. 187 Crores, registering a growth of 34.4% YoY.

Australia and New Zealand Market
Australia and New Zealand businesses reported Rs. 48.6 Crores in Q3FY24, which saw a degrowth of 2.2% on a YoY basis.

RoW Market
RoW business reported Rs 29 Crores in Q3FY24, which grew by 22.2% on a YoY basis.

Key Conference Call Takeaways

  • The management has set a target of achieving revenue of Rs.3000 cr within the next 2 years, following the successful attainment of their initial target guidance of Rs.2000 cr.
  • A portion of the total capex of Rs.200 cr allocated for Teva's Goa plant will spill over to FY25. By the end of FY25, the company's overall capex is expected to remain in the Rs.250 -300 cr range.
  • By March 2024, Teva's manufacturing facility is projected to produce 30 cr tablets. At this run rate, the plant is expected to achieve an annual production capacity of 360 cr tablets. The company is targeting a top-line contribution of Rs. 600 cr from this facility in FY25.
  • The company is comprehensively covering the pain segment with new launches, while the portfolio is being expanded with new launches in digestive, cough and cold, and allergy on the prescription side.
  • As the company’s OTC product pipeline matures, it is witnessing less volatility compared to prescription, which is more susceptible to demand-supply fluctuations. OTC is primarily contract-driven, characterised by longer gestation periods, and extended contractual durations.
  • Australia's growth was muted due to a saturated distribution channel. Given its small market size, growth prospects are expected to remain in the single digits consistently.
  • Surge in freight expenses due to recent sea route disruptions.
  • Plans to file two DMFs for backward integration.
  • Expecting sustainable growth in the US market with new product launches and market penetration, focusing on OTC products in the US market, especially in digestive, cough, and cold segments.
  • Expecting continued revenue growth and margin improvement in the US market due to new product launches and market penetration.
  • Continuous efforts to expand product pipeline with niche, high-value products for bottom-line growth.
  • Focus on complex molecules like adult dual action for future growth and margin improvement.
  • Plans for capex in US and UK facilities to enhance productivity and meet growing demands.

Outlook & valuation

Marksans Pharma recorded healthy earnings performance for the quarter ended Q3FY24. Considering robust R&D capabilities, healthy pipeline of product launches, Strong capabilities and experience to capture a significant part of the multibillion-dollar OTC opportunity, Backward integration, API manufacturing for captive consumption, and focus on inorganic growth, Marksans Pharma is well positioned to deliver steady earnings growth in the coming quarters.

At a CMP of Rs 160, the stock is trading at 16x its FY25e EPS, which appears reasonable and hence we maintain a HOLD rating on the stock.

Quarterly Financials

Particulars (Rs Crores) Q3FY24 Q3FY23 YoY Q2FY24 QoQ
Revenue 586.00 480.00 22.00% 531.00 10.00%
COGS 273.00 239.00 14.00% 253.00 8.00%
Gross Profit 313.00 240.00 30.00% 279.00 12.00%
Gross Profit Margin (%) 53.00% 50.00% 336 bps 52.00% 103 bps
Employee Benefit Expense 75.00 62.00 20.00% 71.00 5.00%
Other Expense 106.00 102.00 4.00% 93.00 13.00%
EBITDA 133.00 77.00 74.00% 114.00 17.00%
EBITDA Margin (%) 23.00% 16.00% 672 bps 21.00% 125 bps
Depreciation and Amortisation 22.00 13.00 73.00% 18.00 25.00%
EBIT 111.00 64.00 74.00% 96.00 15.00%
EBIT Margin (%) 19.00% 13.00% 562 bps 18.00% 80 bps
Finance Cost 3.00 2.00 34.00% 2.00 94.00%
Other Income 5.00 18.00 -73.00% 19.00 -75.00%
PBT 113.00 79.00 42.00% 114.00 -1.00%
Tax 30.00 17.00 76.00% 30.00 -1.00%
PAT 83.00 63.00 31.00% 84.00 0.00%
PAT Margin (%) 14.00% 13.00% 99 bps 16.00% -152 bps
EPS (Rs) 1.84 1.56 18.00% 1.84 0.00%

Source: Company Filings; StockAxis Research

Consolidated Financial statements